phosphonoacetic acid has been researched along with Neoplasms in 37 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
| "Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
| "Eighty-eight patients with advanced cancer were entered into this Phase I trial." | 2.68 | Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. ( Capizzi, RL; Case, L; Fernandes, DJ; Fleming, RA; Homesley, H; Loggie, BW; Morris, R; Muss, HB; Richards, F; Russell, GB; Smith, S, 1996) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "However, the great majority of human cancers undergo disruption of the p53-network." | 1.39 | N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy. ( Agarwal, MK; Agarwal, ML; Gupta, K; Ruhul Amin, AR; Shin, DM; Thakur, VS; Wald, DN, 2013) |
| "Hyperthermia plays an important role in cancer therapy." | 1.38 | Heat induces gene amplification in cancer cells. ( Dewhirst, M; Huang, C; Li, C; Liu, F; Neill, D; Ouyang, R; Yan, B, 2012) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "Fifteen patients with advanced solid tumors participated in a phase I study of a biochemically designed combination chemotherapy program which employed PALA and thymidine (TdR) with 5-FU." | 1.27 | Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU. ( Casper, ES; Kemeny, N; Martin, DS; Michaelson, RA; Young, CW, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (51.35) | 18.7374 |
| 1990's | 14 (37.84) | 18.2507 |
| 2000's | 2 (5.41) | 29.6817 |
| 2010's | 2 (5.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Ruhul Amin, AR | 1 |
| Thakur, VS | 1 |
| Gupta, K | 1 |
| Agarwal, MK | 1 |
| Wald, DN | 1 |
| Shin, DM | 1 |
| Agarwal, ML | 1 |
| Yan, B | 1 |
| Ouyang, R | 1 |
| Huang, C | 1 |
| Liu, F | 1 |
| Neill, D | 1 |
| Li, C | 1 |
| Dewhirst, M | 1 |
| Mathew, R | 1 |
| Kongara, S | 1 |
| Beaudoin, B | 1 |
| Karp, CM | 1 |
| Bray, K | 1 |
| Degenhardt, K | 1 |
| Chen, G | 1 |
| Jin, S | 1 |
| White, E | 1 |
| Galasso, GJ | 1 |
| Pawlicki, M | 1 |
| Zuchowska-Vogelgesang, B | 1 |
| Ardalan, B | 3 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Presant, CA | 1 |
| Martin, DS | 6 |
| Stolfi, RL | 2 |
| Sawyer, RC | 2 |
| Spiegelman, S | 1 |
| Young, CW | 4 |
| Casper, ES | 2 |
| Michaelson, RA | 1 |
| Kemeny, N | 2 |
| Baillon, J | 1 |
| Guichard, M | 1 |
| Malaise, EP | 1 |
| Hervé, G | 1 |
| Erlichman, C | 2 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 2 |
| Weiss, GR | 1 |
| Ervin, TJ | 2 |
| Meshad, MW | 1 |
| Schade, D | 1 |
| Branfman, AR | 2 |
| Bruni, RJ | 2 |
| Chadwick, M | 2 |
| Kufe, DW | 1 |
| Moore, EC | 2 |
| Friedman, J | 2 |
| Valdivieso, M | 2 |
| Plunkett, W | 1 |
| Marti, JR | 2 |
| Russ, J | 1 |
| Loo, TL | 2 |
| Leyva, A | 2 |
| Appel, H | 1 |
| Smith, P | 1 |
| Lankelma, J | 1 |
| Pinedo, HM | 2 |
| Stewart, D | 1 |
| Merrill, YN | 1 |
| Strong, JM | 2 |
| Gralla, RJ | 1 |
| Natale, RB | 1 |
| Yagoda, A | 1 |
| Tlsty, TD | 2 |
| White, A | 2 |
| Livanos, E | 2 |
| Sage, M | 2 |
| Roelofs, H | 2 |
| Briot, A | 2 |
| Poulose, B | 2 |
| Machover, D | 1 |
| Hageboutros, A | 2 |
| Rogatko, A | 1 |
| Newman, EM | 1 |
| McAleer, C | 1 |
| Brennan, J | 2 |
| LaCreta, FP | 3 |
| Hudes, GR | 3 |
| Ozols, RF | 3 |
| O'Dwyer, PJ | 5 |
| Jonczyk, P | 1 |
| Hall, I | 1 |
| Schaefer, D | 1 |
| Seiter, K | 1 |
| Martin, D | 1 |
| Schneider, A | 2 |
| Williams, L | 1 |
| Colofiore, J | 3 |
| Sawyer, R | 1 |
| Green, F | 1 |
| Hoffman, J | 2 |
| Fleming, RA | 1 |
| Capizzi, RL | 1 |
| Muss, HB | 1 |
| Smith, S | 1 |
| Fernandes, DJ | 1 |
| Homesley, H | 1 |
| Loggie, BW | 1 |
| Case, L | 1 |
| Morris, R | 1 |
| Russell, GB | 1 |
| Richards, F | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Osman, S | 1 |
| Brown, G | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Jones, T | 1 |
| Price, PM | 1 |
| Wiernik, PH | 1 |
| McAvoy, LM | 1 |
| Cohen, MH | 1 |
| Levine, AS | 1 |
| Hubbard, SM | 1 |
| Von Hoff, DD | 1 |
| Walczak, J | 1 |
| Comis, RL | 1 |
| Stridhar, K | 1 |
| Reddy, R | 1 |
| Benedetto, P | 2 |
| Richman, S | 2 |
| Waldman, S | 2 |
| Morrell, L | 2 |
| Feun, L | 2 |
| Savaraj, N | 2 |
| Livingstone, A | 2 |
| Sridhar, KS | 1 |
| Fodor, M | 1 |
| Kemeny, NE | 1 |
| Peters, GJ | 1 |
| Laurensse, E | 1 |
| King, SA | 1 |
| Hoth, DF | 1 |
| Leyland-Jones, B | 1 |
| Chan, TC | 2 |
| Markman, M | 2 |
| Cleary, S | 2 |
| Howell, SB | 2 |
8 reviews available for phosphonoacetic acid and Neoplasms
| Article | Year |
|---|---|
Antiviral agents: the road from scepticism to efficacy.
Topics: Acyclovir; Amantadine; Antiviral Agents; Bromodeoxyuridine; Clinical Trials as Topic; Guanine; Hepat | 1981 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interfer | 1982 |
Genomic integrity and the genetics of cancer.
Topics: Adenovirus E1A Proteins; Adenoviruses, Human; Antimetabolites; Apoptosis; Aspartic Acid; Cell Cycle; | 1994 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
New mechanisms of gene amplification in drug resistance (the episome model).
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; ATP Binding Cassette | 1991 |
The role of low-dose PALA in biochemical modulation.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, | 1990 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1987 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
8 trials available for phosphonoacetic acid and Neoplasms
| Article | Year |
|---|---|
Antiviral agents: the road from scepticism to efficacy.
Topics: Acyclovir; Amantadine; Antiviral Agents; Bromodeoxyuridine; Clinical Trials as Topic; Guanine; Hepat | 1981 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1996 |
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoylt | 1996 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Biops | 1991 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
24 other studies available for phosphonoacetic acid and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Bcl-2-Like | 2013 |
Heat induces gene amplification in cancer cells.
Topics: Acid Anhydride Hydrolases; Acylphosphatase; Aspartate Carbamoyltransferase; Aspartic Acid; Dihydroor | 2012 |
Autophagy suppresses tumor progression by limiting chromosomal instability.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Autophagy; Autophagy-Related Prote | 2007 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Drug Therapy, Combination; Female; Fluorouracil; Leuc | 1983 |
Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Fluorouracil; Humans | 1984 |
Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Cell Count; Cell Extracts; Cell Line; Cell-Free Syste | 1983 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Digestive System; Drug Evaluation; D | 1982 |
Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Evaluation; Hum | 1982 |
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell L | 1981 |
Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Creatinine; Drug Evaluation; Humans; Metabolic Cleara | 1980 |
Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Topics: Antineoplastic Agents; Aspartic Acid; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms; Organ | 1980 |
Phase I trial of PALA.
Topics: Antineoplastic Agents; Aspartic Acid; Brain Diseases; Diarrhea; Dose-Response Relationship, Drug; Ga | 1980 |
Loss of chromosomal integrity in neoplasia.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation | 1979 |
Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; In | 1992 |
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1990 |
The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Fluorouracil; Humans; Methotrexate; Neoplasms; O | 1985 |
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyridamole; Drug Evaluation; Female | 1986 |
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyr | 1987 |